Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting;

Irving, Julie; Jesson, Jenny; Virgo, Paul; Case, Marian; Minto, Lynne; Eyre, Lisa; Noel, Nigel; Johansson, Ulrika; Macey, Marion G.; Knotts, Linda L.; Helliwell, Margaret; Davies, Paul; Whitby, Liam; Barnett, David; Hancock, Jeremy; Goulden, Nick; Lawson, Sarah

doi:10.3324/haematol.2008.000414

Cited by 92 publications

(108 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The use of patient-derived leukemia cells was approved by regional ethical committee approval for Australian and UK samples. Minimal residual disease in BCP-ALL patients, 28 days after start of treatment, was measured as described previously (35).…”

Section: Methodsmentioning

confidence: 99%

p53-independent Epigenetic Repression of the p21WAF1 Gene in T-cell Acute Lymphoblastic Leukemia

Davies

Hogarth

Dietrich

et al. 2011

Journal of Biological Chemistry

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

p53-independent Epigenetic Repression of the p21WAF1 Gene in T-cell Acute Lymphoblastic Leukemia

Davies

Hogarth

Dietrich

et al. 2011

Journal of Biological Chemistry

View full text Add to dashboard Cite

show abstract

“…Flow cytometric and molecular methods that allow sensitive detection and specific quantification of residual leukemic cells have been developed. [28][29][30][31][32][33][34][35][36][37][38][39][40] Standardization of methodologies and definitions of common MRD terms become increasingly important, not only to ensure comparability of MRD data between different MRD laboratories within a single MRD-based treatment protocol but also to provide a sound basis for the comparison of MRD results between different treatment protocols, including those that evaluate the effectiveness of new agents.…”

Section: Introductionmentioning

confidence: 99%

Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008

et al. 2009

View full text Add to dashboard Cite

Assessment of minimal residual disease (MRD) has acquired a prominent position in European treatment protocols for patients with acute lymphoblastic leukemia (ALL), on the basis of its high prognostic value for predicting outcome and the possibilities for implementation of MRD diagnostics in treatment stratification. Therefore, there is an increasing need for standardization of methodologies and harmonization of terminology. For this purpose, a panel of representatives of all major European study groups on childhood and adult ALL and of international experts on PCR-and flow cytometry-based MRD assessment was built in the context of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. The panel summarized the current state of MRD diagnostics in ALL and developed recommendations on the minimal technical requirements that should be fulfilled before implementation of MRD diagnostics into clinical trials. Finally, a common terminology for a standard description of MRD response and monitoring was established defining the terms 'complete MRD response', 'MRD persistence' and 'MRD reappearance'. The proposed MRD terminology may allow a refined and standardized assessment of response to treatment in adult and childhood ALL, and provides a sound basis for the comparison of MRD results between different treatment protocols.

show abstract

“…Our results showed under expression of CD45 (on CD34 +ve blasts) was found in 60.1% of patients. Also Irving et al [14] found the under expression of CD45 to be useful in 75% of B-ALL. Patkar et al [12] (2012) found that CD20, CD10, CD19 and CD45 combination was applicable to 71.4% of B-ALL cases.…”

Section: Discussionmentioning

confidence: 99%

“…CD22 when seen solely as a marker of aberrant expression seems to be of limited utility as shown by Campana D (13). (20-30%), Irving et al, [13,14] (5%). Loretta et al [15] however reported a much higher applicability of 46.2%.…”

Section: Discussionmentioning

confidence: 99%

Detection of Minimal Residual Disease in Childhood B-Acute Lymphoblastic Leukemia by 4-Color Flow Cytometry

Baraka¹,

Sherief²,

Kamal³

et al. 2017

J Hematol Thrombo Dis

View full text Add to dashboard Cite

Monitoring of minimal residual disease (MRD) is today considered the most powerful predictor of outcome in acute leukemias, including acute lymphoblastic leukemia (ALL). The study aimed to determine whether panel of antibodies combination are more suitable than others for detection of MRD in Childhood B-lineage ALL. Eighty four (84) patients of ALL (B-lineage subtype) were enrolled in this study. Normal template for B. Cell precursors were been established in 15 control Patients by using 4 panels of monoclonal Abs (Mo Abs), {CD22, CD45, CD58 and CD97 in combination with CD10, CD19, CD34}. At diagnosis CD22 having the lowest incidence expression between the patients in 50% only, but CD45, CD58, and CD97 were expressed in 80.9%, 52.3% and 92.8% respectively. Analysis of MRD was performed for each Mo Abs combination at day 0 and day 14 post induction of chemotherapy by 4-color flow cytometer (FCM). The incidence of MRD were 61.9%, 70.6%, 60.0% and 55.5% for CD22,CD45,CD58 and CD97 respectively. Seventy-six from total 84 cases studied (90.0%) had at least one LAIP. Of these, 22 (29.0%) had only one LAIP and 54 cases (71.0%) had ≥ 2 LAIPS Conclusion: In the B-ALL patients (CD10/CD19/CD34/CD45)+ and (CD10/CD19/CD34/CD97)+, represented the highest incidence markers expression of leukemic cells with a significant correlation with blasts count, so it's the more specific for MRD detection.

show abstract

Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting;

Cited by 92 publications

References 31 publications

p53-independent Epigenetic Repression of the p21WAF1 Gene in T-cell Acute Lymphoblastic Leukemia

p53-independent Epigenetic Repression of the p21WAF1 Gene in T-cell Acute Lymphoblastic Leukemia

Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008

Detection of Minimal Residual Disease in Childhood B-Acute Lymphoblastic Leukemia by 4-Color Flow Cytometry

Contact Info

Product

Resources

About